Want to see PHVS full AI Analyst Report?
Top Page
Pharvaris
(NASDAQ:PHVS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$34.00
▲(18.96% Upside)
Action:Reiterated
Date:05/15/26
The score is primarily held back by weak financial performance driven by no revenue, widening losses, and rising cash burn (funding risk), partially offset by low balance-sheet leverage. Technicals are supportive with price above major moving averages and positive MACD, while valuation remains constrained by ongoing losses and no dividend.
Positive Factors
Late-stage pipeline progress
Progressing from early development into pivotal Phase 3 and an imminent U.S. NDA materially increases the company's pathway to commercialization. Sustained late-stage momentum reduces binary scientific risk, shifts strategic priorities to regulatory execution and market access, and supports durable value creation if approvals succeed.
Negative Factors
Pre-revenue with widening losses
The company remains pre-revenue with materially widening net losses, which steadily erode shareholder equity and limit the ability to self-fund commercialization. Persistent operating deficits create a durable need for external capital and heighten execution risk if clinical or regulatory timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage pipeline progress
Progressing from early development into pivotal Phase 3 and an imminent U.S. NDA materially increases the company's pathway to commercialization. Sustained late-stage momentum reduces binary scientific risk, shifts strategic priorities to regulatory execution and market access, and supports durable value creation if approvals succeed.
Read all positive factors
Pharvaris (PHVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.37B
Dividend YieldN/A
Average Volume (3M)347.46K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS Growth-5.22%
CountryUS
Employees129
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.83
Shares Outstanding69,863,686
10 Day Avg. Volume329,608
30 Day Avg. Volume347,462
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.73K
Enterprise Value/Ebitda-10.68
Forecast
1Y Price Target
$49.60Price Target Upside73.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.61
Revenue Forecast (FY)N/A
Pharvaris Business Overview & Revenue Model
Company Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Pharvaris does not have a stable, ongoing product-revenue stream from marketed drugs (null). Its cash inflows are primarily generated through financing activities rather than operations, including: (1...
Pharvaris Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -173.29M | -145.59M | -99.57M | -86.56M | -42.31M |
| Net Income | -175.70M | -134.22M | -100.88M | -76.33M | -42.73M |
Balance Sheet | |||||
| Total Assets | 301.45M | 291.37M | 398.69M | 167.73M | 212.09M |
| Cash, Cash Equivalents and Short-Term Investments | 291.68M | 280.73M | 391.23M | 161.84M | 209.35M |
| Total Debt | 776.80K | 861.47K | 238.91K | 436.82K | 250.18K |
| Total Liabilities | 30.18M | 23.61M | 14.65M | 18.47M | 7.14M |
| Stockholders Equity | 271.27M | 267.76M | 384.05M | 149.26M | 204.95M |
Cash Flow | |||||
| Free Cash Flow | -137.24M | -120.67M | -93.14M | -67.29M | -44.73M |
| Operating Cash Flow | -137.07M | -120.13M | -93.05M | -67.16M | -44.60M |
| Investing Cash Flow | -164.62K | -538.09K | -89.98K | -124.30K | -130.03K |
| Financing Cash Flow | 160.61M | 2.68M | 325.39M | 8.65M | 143.67M |
Pharvaris Technical Analysis
Positive
28.58
Price Trends
30.94
Positive
29.12
Positive
26.92
Positive
Market Momentum
1.04
Negative
61.02
Neutral
55.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Positive. The current price of 28.58 is below the 20-day moving average (MA) of 32.67, below the 50-day MA of 30.94, and above the 200-day MA of 26.92, indicating a bullish trend. The MACD of 1.04 indicates Negative momentum. The RSI at 61.02 is Neutral, neither overbought nor oversold. The STOCH value of 55.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHVS.
Pharvaris Risk Analysis
Pharvaris disclosed 82 risk factors in its most recent earnings report. Pharvaris reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our articles of association designate specific courts as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. Q4, 2023
2.
to successfully commercialize our product candidates, or experience significant delays in doing so, our business, financial condition, results of operations and prospects would be materially adversely affected. Q4, 2023
Pharvaris Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $4.26B | -23.83 | -32.55% | ― | ― | -7.28% | |
62 Neutral | $2.50B | -5.69 | 123.57% | ― | 75.92% | -569.22% | |
56 Neutral | $3.01B | -8.99 | -50.72% | ― | -88.54% | -58.13% | |
52 Neutral | $2.37B | -10.47 | -67.40% | ― | ― | -5.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.14B | -5.57 | -60.70% | ― | 23382.78% | 7.01% | |
49 Neutral | $2.40B | -2.81 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
PHVS
Pharvaris
33.86
15.26
82.04%
BCRX
BioCryst
9.84
0.90
10.07%
CLDX
Celldex
38.37
16.37
74.41%
VRDN
Viridian Therapeutics
19.40
3.73
23.80%
EWTX
Edgewise Therapeutics
39.56
26.95
213.72%
BHVN
Biohaven Ltd.
15.96
2.17
15.74%
Pharvaris Corporate Events
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
Jun 26, 2026
On June 26, 2026, Pharvaris N.V. held its Annual General Meeting of Shareholders, at which investors approved the Dutch statutory annual accounts for the fiscal year ended December 31, 2025 and discharged directors from liability for their perform...
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
Jun 11, 2026
Pharvaris announced on June 11, 2026, that it will hold its 2026 annual general meeting of shareholders on June 26, 2026, at 16:00 CEST in Zug, Switzerland. The company has made the meeting notice, agenda, proxy materials, and its 2025 annual repo...
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
May 12, 2026
Pharvaris reported first-quarter 2026 results on May 12, 2026, highlighting continued investment in late-stage trials of its oral angioedema drug deucrictibant and preparations for commercialization. The company closed a $132 million underwritten ...
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
May 11, 2026
On May 8, 2026, Pharvaris N.V. signed an underwriting agreement with a syndicate led by Morgan Stanley and Leerink Partners to issue and sell 4,455,863 ordinary shares, including the full exercise of the underwriters’ option, in an underwrit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.